Mallinckrodt plc to Report Earnings Results for Second Quarter 2025
Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.
Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.
Mallinckrodt (NYSE:MNK), un'azienda farmaceutica specializzata a livello globale, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per mercoledì 6 agosto 2025. La società terrà una conference call per gli investitori alle 8:30 ET.
Gli investitori potranno partecipare tramite diversi canali, tra cui un sistema di registrazione per chiamate in diretta e una webcast solo audio. La presentazione sarà inoltre disponibile sul sito web delle Relazioni con gli Investitori di Mallinckrodt.
Mallinckrodt (NYSE:MNK), una compañía farmacéutica especializada a nivel global, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el miércoles 6 de agosto de 2025. La empresa realizará una conferencia telefónica para inversores a las 8:30 a.m. ET.
Los inversores podrán participar a través de varios canales, incluyendo un sistema de registro para llamadas en vivo y una transmisión en línea solo de audio. La presentación también estará disponible en el sitio web de Relaciones con Inversores de Mallinckrodt.
Mallinckrodt (NYSE:MNK)는 글로벌 전문 제약회사로서 2025년 2분기 재무 실적 발표를 2025년 8월 6일 수요일로 예정했습니다. 회사는 동부 표준시 오전 8시 30분에 투자자 컨퍼런스 콜을 개최할 예정입니다.
투자자들은 라이브 전화 등록 시스템과 오디오 전용 웹캐스트 등 다양한 채널을 통해 참여할 수 있습니다. 발표 자료는 Mallinckrodt 투자자 관계 웹사이트에서도 확인할 수 있습니다.
Mallinckrodt (NYSE:MNK), une entreprise pharmaceutique spécialisée à l’échelle mondiale, a programmé l’annonce de ses résultats financiers du deuxième trimestre 2025 pour le mercredi 6 août 2025. La société organisera une conférence téléphonique pour les investisseurs à 8h30 ET.
Les investisseurs pourront participer via plusieurs canaux, y compris un système d’inscription pour appels en direct et un webcast audio uniquement. La présentation sera également accessible sur le site des Relations Investisseurs de Mallinckrodt.
Mallinckrodt (NYSE:MNK), ein globales Spezialpharmaunternehmen, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Mittwoch, den 6. August 2025 angekündigt. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz für Investoren abhalten.
Investoren können über verschiedene Kanäle teilnehmen, darunter ein Live-Anmeldesystem für Telefonate und einen reinen Audio-Webcast. Die Präsentation wird auch auf der Investor-Relations-Website von Mallinckrodt verfügbar sein.
- None.
- None.
A conference call for investors will begin at 8:30 a.m. ET and can be accessed as follows:
- Live Call Participant Registration (including dial-in):
https://dpregister.com/sreg/10201457/ff90cf5afd
- Audio-Only Webcast Link (live and replay: https://edge.media-server.com/mmc/p/jpzqwkm8
- On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Investor Relations Contact
Bryan Reasons
Executive Vice President and Chief Financial Officer
bryan.reasons@mnk.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-second-quarter-2025-302509590.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) report Q2 2025 earnings?
What time is Mallinckrodt's Q2 2025 earnings call?
How can investors access Mallinckrodt's Q2 2025 earnings call?
Where can I find Mallinckrodt's Q2 2025 earnings webcast?
